Multiples aberrant phenotypes in multiple myeloma patient expressing CD56&lt;sup&gt;-&lt;/sup&gt;, CD28&lt;sup&gt;+&lt;/sup&gt;,CD19&lt;sup&gt;+&lt;/sup&gt;

Leite, Luiz Arthur Calheiros; Kerbauy, Daniela Márcia Bahia; Kimura, Eliza Yuriko Sugano; Yamamoto, Masahiro

doi:10.5581/1516-8484.20120019

Cited by 5 publications

(1 citation statement)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation of CD117 expression with hyperdiploidy was found as well [73]. The expression of CD117 on PCs is associated with changes in production of haematopoietic stem cells from BM, lead to a decreasing number of neutrophils in PB and the presence of normal PCs in BM [57] [74]. The very important genetic change in MM is loss of the gene for CD27 which is linked with clinically aggressive disease, but in about 50% of MM is expression of CD27 preserved and these patients have better prognosis [44].…”

Section: Prognostic Markers In Mgsmentioning

confidence: 97%

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies

Říhová¹,

Raja²,

Leite³

et al. 2013

Multiple Myeloma - A Quick Reflection on the Fast Progress

View full text Add to dashboard Cite

Section: Prognostic Markers In Mgsmentioning

confidence: 97%

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies

Říhová¹,

Raja²,

Leite³

et al. 2013

Multiple Myeloma - A Quick Reflection on the Fast Progress

View full text Add to dashboard Cite

A case of multiple myeloma diagnosed by extramedullary disease in the submandibular region

Koizumi

Taishi

Nakase

et al. 2023

Journal of Oral and Maxillofacial Surgery, Medicine, and Pathol

View full text Add to dashboard Cite

Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?

Tannoury

Garnier

Susin

et al. 2022

Cancers

View full text Add to dashboard Cite

Resistance to death is one of the hallmarks of human B cell malignancies and often contributes to the lack of a lasting response to today’s commonly used treatments. Drug discovery approaches designed to activate the death machinery have generated a large number of inhibitors of anti-apoptotic proteins from the B-cell lymphoma/leukemia 2 family and the B-cell receptor (BCR) signaling pathway. Orally administered small-molecule inhibitors of Bcl-2 protein and BCR partners (e.g., Bruton’s tyrosine kinase and phosphatidylinositol-3 kinase) have already been included (as monotherapies or combination therapies) in the standard of care for selected B cell malignancies. Agonistic monoclonal antibodies and their derivatives (antibody–drug conjugates, antibody–radioisotope conjugates, bispecific T cell engagers, and chimeric antigen receptor-modified T cells) targeting tumor-associated antigens (TAAs, such as CD19, CD20, CD22, and CD38) are indicated for treatment (as monotherapies or combination therapies) of patients with B cell tumors. However, given that some patients are either refractory to current therapies or relapse after treatment, novel therapeutic strategies are needed. Here, we review current strategies for managing B cell malignancies, with a focus on the ongoing clinical development of more effective, selective drugs targeting these molecules, as well as other TAAs and signaling proteins. The observed impact of metabolic reprogramming on B cell pathophysiology highlights the promise of targeting metabolic checkpoints in the treatment of these disorders.

show abstract

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56<sup>-</sup>, CD28<sup>+</sup>,CD19<sup>+</sup>

Cited by 5 publications

References 8 publications

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies

A case of multiple myeloma diagnosed by extramedullary disease in the submandibular region

Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?

Contact Info

Product

Resources

About